Skip to search formSkip to main contentSkip to account menu

loxiglumide

Known as: (+-)-4-((3,4-Dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxopentanoic Acid, 4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropylpentylamino)-5-oxopentanoic acid, D,L-4-(3,4-Dichlorobenzoylamino)-5-(N-3-methoxypropylpentylamino)-5-oxo-pentanoic Acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
When pancreaticobiliary diversion (PBD) surgery was performed in rats, plasma CCK level increased, the pancreas grew mainly by… 
Review
1999
Review
1999
Among the most important topics attracting investigators' attention in 1998 were gastroesophageal reflux disease (GERD), the… 
1998
1998
We examined the effects of treatment with cholecystokinin (CCK) octapeptide (CCK-8) and the CCK receptor antagonist loxiglumide… 
1994
1994
Objective Assessment of the effect of the cholecystokinin-receptor antagonist, loxiglumide, on proximal colon transit in normal… 
1992
1992
MOTOR RESPONSES OF HUMAN ILEUM TO TACHYKININS IN VITRO: EXISTENCE OF NK2 RECEPTORS AND RECEPTORS SPECIFIC FOR NEUROPEPTIDE GAMMA. 
1991
1991
The recent development of antagonists of cholecystokinin (CCK) has not only generated great interest in the scientific and… 
1989
1989
The effect of a new proglumide derivative, loxiglumide (DL-4-(3,4-dichloro-benzoyl-amino)-5-(N-3-methoxy-propyl-pentylamino…